Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation

a cholinergic agonist and vagus nerve technology, applied in the field of reducing inflammation, can solve the problems of efferent neural pathway role, comparatively little is known about the role of efferent neural pathway, and no evidence that cholinergic agonists can inhibit inflammatory cytokines, and achieve the effect of inhibiting the release of proinflammatory cytokines and inhibiting the cascade of inflammatory cytokines

Inactive Publication Date: 2009-10-01
THE FEINSTEIN INST FOR MEDICAL RES
View PDF99 Cites 103 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in many disease conditions, this internal homeostasis becomes out of balance.
However, comparatively little is known about the role of efferent neural pathways that can modulate inflammation.
However, none of these findings would suggest that cholinergic agonists can inhibit an inflammatory cytokine cascade, particularly those mediated by macrophages.
Also, there is no suggestion in the literature that efferent vagus nerve stimulation is effective in inhibiting these cascades.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
  • Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
  • Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation

Examples

Experimental program
Comparison scheme
Effect test

example 1

Cholinergic Agonists Inhibit Release of Proinflammatory Cytokines from Macrophages

1. Materials and Methods

[0064]Human macrophage cultures were prepared as follows. Buffy coats were collected from the blood of healthy individual donors to the Long Island Blood Bank Services (Melville, N.Y.). Primary blood mononuclear cells were isolated by density-gradient centrifugation through Ficoll / Hypaque (Pharmacia, N.J.), suspended (8.times.10.sup.6 cells / ml) in RPMI 1640 medium supplemented with 10% heat inactivated human serum (Gemini Bio-Products, Inc., Calabasas, Calif.), and seeded in flasks (PRIMARIA; Beckton and Dickinson Labware, Franklin Lakes, N.J.). After incubation for 2 hours at 37.degree. C., adherent cells were washed extensively, treated briefly with 10 mM EDTA, detached, resuspended (10.sup.6 cells / ml) in RPMI medium (10% human serum), supplemented with human macrophage colony stimulating factor (MCSF; Sigma Chemical Co., St. Louis, Mo.; 2 ng / ml), and seeded onto 24-well tissu...

example 2

Inhibition of Endotoxic Shock by Stimulation of Efferent Vagus Nerve Fibers

[0079]To determine whether direct stimulation of efferent vagus nerve activity might suppress the systemic inflammatory response to endotoxin, adult male Lewis rats were subjected to bilateral cervical vagotomy, or a comparable sham surgical procedure in which the vagus nerve was isolated but not transected. Efferent vagus nerve activity was stimulated in vagotomized rats by application of constant voltage stimuli to the distal end of the divided vagus nerve 10 min before and again 10 min after the administration of a lethal LPS dose (15 mg / kg, i.v.). An animal model of endotoxic shock was utilized in these experiments. Adult male Lewis rats (280-300 g, Charles River Laboratories, Wilmington, Mass.) were housed at 22.degree. C. on a 12 h light / dark cycle. All animal experiments were performed in accordance with the National Institute of Health Guidelines under the protocols approved by the Institutional Anima...

example 3

Stimulation of Intact Vagus Nerve Attenuates Endotoxic Shock

[0088]Experiments were conducted to determine whether the inhibition of inflammatory cytokine cascades by efferent vagus nerve stimulation is effective by stimulation of an intact vagus nerve. Stimulation of left and right vagus nerves were also compared.

[0089]The vagus nerves of anesthetized rats were exposed, and the left common iliac arteries were cannulated to monitor blood pressure and heart rate. Endotoxin (E. coli 0111:B4; Sigma) was administered at a lethal dose (60 mg / kg). In treated animals, either the left or the right intact vagus nerve was stimulated with constant voltage (5V or 1V, 2 ms, 1 Hz) for a total of 20 min., beginning 10 min. before and continuing 10 min. after LPS injection. Blood pressure and heart rate were through the use of a Bio-Pac M100 computer-assisted acquisition system. FIGS. 12-14 show the results of these experiments.

[0090]As shown in FIG. 12, within minutes after LPS injection, the blood...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
concentrationsaaaaaaaaaa
voltageaaaaaaaaaa
Login to View More

Abstract

A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. Ser. No. 10 / 990,938, filed Nov. 17, 2004, which is a continuation-in-part of U.S. Ser. No. 10 / 466,625 filed May 28, 2003, now U.S. Pat. No. 6,838,471; which is a continuation of U.S. Ser. No. 09 / 855,446, filed May 15, 2001, now U.S. Pat. No. 6,610,713; which claims priority to Provisional Application No. 60 / 206,364 filed May 23, 2000, the disclosures of which are incorporated herein by reference into the present application.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention generally relates to methods of reducing inflammation. More specifically, the invention relates to methods for reducing inflammation caused by proinflammatory cytokines or an inflammatory cytokine cascade.[0004]2. Description of the Related Art[0005]Vertebrates achieve internal homeostasis during infection or injury by balancing the activities of proinflammatory and anti-inflammatory pathways. However, in many ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61N1/02A61K31/44
CPCA61K31/44A61N1/3606Y02A50/30A61N1/36053A61N1/36167
Inventor TRACEY KEVIN J.HUSTON JARED M.
Owner THE FEINSTEIN INST FOR MEDICAL RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com